Brief: Johns Hopkins Medicine Initiates Patient Enrollment For Renovorx’S Ongoing Phase III Tiger-Pac Clinical Trial
29/04/2025 13:39
April 29 (Reuters) - RenovoRx Inc RNXT.O: JOHNS HOPKINS MEDICINE INITIATES PATIENT ENROLLMENT FOR RENOVORX’S ONGOING PHASE III TIGER-PAC CLINICAL TRIAL RENOVORX INC - EXPECTS FULL ENROLLMENT FOR TIGER-PAC TRIAL IN 2025 Source text: ID:nBwbHZsKla Further company coverage: RNXT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer
RenovoRx Q1 revenue rises as number of active cancer centers increase
RenovoRx 2025 net loss widens on higher operating expenses
Brief: RenovoRx FY Net Income USD -11.168 Million
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies